Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Feb 28;13:808322. doi: 10.3389/fneur.2022.808322

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2022 Lin, Chang, Lin, Sun, Wei, Zhao, Liu, Yang and Li.

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The proportion of CD19⁺ IL-10⁺ cells in peripheral blood cells of MG patients and controls. (A) Lymphocytes were gated according to forward scatter and side scatter by FCM. (B) B cells were gated according to CD19⁺ in lymphocytes. (D) Scatter plots show the mean percentages of CD19⁺ IL-10⁺ cells in the peripheral blood of 23 OMG patients, 18 GMG patients, and 30 healthy individuals. (E) Expression of IL-10 mRNA by real-time quantitative analysis in the peripheral blood of 8 MG patients and 8 healthy individuals. Six of 8 MG patients were ocular myasthenia gravis. (C) Representative flow cytometry plot of CD19⁺ IL-10⁺ cell gating for patients with OMG, GMG, and healthy controls. (F) The frequency of CD19+ IL-10+ cell in different MG types according to age at onset. (G) The frequency of CD19⁺ IL-10⁺ cells in different thymus status. (H) The frequency of CD19⁺ IL-10⁺ cells in different gender. (I) The titer of anti-AChR antibody in MG patients, including 21 healthy controls, 23 OMG patients, and 18 GMG patients. (J) The proportion of CD19⁺ IL-10⁺ cells had no correlation with the level of anti-AChR antibody, and the samples were from 41 patients with MG. p-values were calculated by Student's t-test; *p < 0.05, **p < 0.01, ***p < 0.001, ns, not significant.